Mesenchymal Stem Cells in Central Nervous System Injury

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Fuzhou General Hospital
ClinicalTrials.gov Identifier:
NCT01719640
First received: October 6, 2012
Last updated: October 30, 2012
Last verified: October 2012

October 6, 2012
October 30, 2012
January 2011
January 2014   (final data collection date for primary outcome measure)
life quality score [ Time Frame: 1y ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01719640 on ClinicalTrials.gov Archive Site
adverse events [ Time Frame: 1y ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Mesenchymal Stem Cells in Central Nervous System Injury
Intrathecal Injection of Mesenchymal Stem Cells in Central Nervous System Injury

Central nervous system (CNS) injury leads to morbidity in patients, which has few good rehabilitation measures. Mesenchymal stem cells seem to have regenerative and tissue-repairing capabilities. The investigators design this study to infuse mesenchymal stem cells (MSCs) intrathecally to CNS injury patients, and observe the safety and efficacy by recording the change of nervous system scores, trying to prove the effect of MSC in rehabilitate CNS injury.

Not Provided
Interventional
Phase 0
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Central Nervous System Injury
Biological: infusion of MSCs
Experimental: MSC
infusion of MSCs at day 0, 7, 14, 21
Intervention: Biological: infusion of MSCs
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
January 2018
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • CNS injury > 3 months
  • age > 18 years
  • willing to give consent

Exclusion Criteria:

  • any contradiction to intrathecal infusion
  • age < 18 years
  • CNS injury < 3 months
  • CNS injury > 3 years
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT01719640
MSC-CNS
Yes
Fuzhou General Hospital
Fuzhou General Hospital
Not Provided
Not Provided
Fuzhou General Hospital
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP